Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.51 |
| ▸ | DRD3 | P35462 | 14/20 | 0.48 |
| ▸ | HTR2A | P28223 | 12/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3157844 | 0.94 | DRD2 (0.47) | DRD2DRD3HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3145983 | 0.94 | DRD2 (0.50) | DRD2DRD3HTR2A | |
| SCHEMBL3044402 | 0.92 | DRD2 (0.43) | DRD2DRD3HTR2A | |
| SCHEMBL3154271 | 0.91 | DRD2 (0.44) | DRD2DRD3HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3143699 | 0.90 | DRD2 (0.47) | DRD2DRD3HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3143255 | 0.86 | DRD2 (0.47) | DRD2DRD3HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3149321 | 0.85 | KMT2A (0.47) | DRD2DRD3HTR2ALMNASMN1; SMN2 | |
| SCHEMBL3148961 | 0.85 | DRD3 (0.46) | DRD2DRD3HTR2A | |
| SCHEMBL3147825 | 0.85 | DRD3 (0.44) | DRD2DRD3HTR2A | |
| SCHEMBL3277557 | 0.85 | NPC1 (0.45) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | DRD2 424/4885DRD3 467/4885HTR2A 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.